Selected Publications

  1. Reeves D, Reeves DB, Duke ER, Hughes SM, Prlic M, Hladik F*, Schiffer JT* (*contributed equally). Anti-proliferative therapy for HIV cure: a compound interest approach. Scientific Reports 21;7(1):4011 (2017).    
  2. Hughes SM, Shu Z, Levy CN, Ferre AL, Hartig H, Fang C, Lentz G, Fialkow M, Kirby AC, Adams Waldorf KM, Veazey RS, Germann A, von Briesen H, McElrath MJ, Dezzutti CS, Sinclair E, Baker CAR, Shacklett BL, Gao D, Hladik F. Cryopreservation of human mucosal leukocytes. PLoS One:11(5):e0156293 (2016).
  3. Hladik F. A new hypothesis on HIV cure. F1000Research, 4:77 (2015).
  4. Hladik F, Burgener A, Ballweber L, Gottardo R, Vojtech L, Fourati S, Dai JY, Cameron MJ, Strobl J, Hughes SM, Hoesley C, Andrew P, Johnson S, Piper J, Friend DR, Ball TB, Cranston RD, Mayer KH, McElrath MJ, McGowan I. Mucosal effects of tenofovir 1% gel. eLife 4:e04525 (2015).
  5. Chevillet JR, Kanga Q, Ruf IK, Briggs HA, Vojtech L, Hughes S, Cheng HH, Arroyo JD, Meredith EK, Gallichotte EN, Pogosova-Agadjanyan EL, Morrissey C, Stirewalt DL, Hladik F, Yu EY, Higano CS, Tewari M. Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proceedings of the National Academy of Sciences USA, 111:14888-93 (2014).
  6. Seaton KE, Ballweber L, Lan A, Donathan M, Moody MA, Liao HX, Haynes BF, Hughes S, Vojtech L, Galloway CG, Richardson B.A., Karim SA, Dezzutti CS, McElrath MJ, Tomaras GD, Hladik F. Mucosal HIV-1-specific IgA in HIV uninfected women participating in a microbicide trial in Southern Africa. PLOS One, 9:e101863 (2014). Part of the collection “Advances in HIV Mucosal Immunology: Challenges and Opportunities”.
  7. Mitchell CM, McLemore L, Westerberg K, Astronomo R, Smythe K, Gardella C, Mack M, Magaret A, Patton D, Agnew K, McElrath MJ, Hladik F*, Eschenbach D* (contributed equally). Long-term effect of depot medroxyprogesterone acetate on vaginal microbiota, epithelial thickness and HIV target cells. Journal of Infectious Diseases 210:651-5 (2014).
  8. Vojtech L, Woo, S, Hughes S, Levy C, Ballweber L, Sauteraud RP, Strobl J, Westerberg K, Gottardo R, Tewari M, Hladik F. Exosomes in human semen carry a distinctive repertoire of small non-coding RNAs with potential regulatory functions. Nucleic Acids Research 42:7290-7304 (2014).
  9. McKinnon LR, Hughes SM, De Rosa SC, Martinson JA, Plants J, Brady KE, Gumbi PP, Adams DJ, Vojtech L, Galloway CG, Fialkow M, Lentz G, Gao D, Shu Z, Nyanga B, Izulla P, Kimani J, Kimwaki S, Bere A, Moodie Z, Landay AL, Passmore JA, Kaul R, Novak RM, McElrath MJ, Hladik F. Optimizing viable leukocyte sampling from the female genital tract for clinical trials: an international multi-site study. PLOS One 9:e85675 (2014). Part of the collection “Advances in HIV Mucosal Immunology: Challenges and Opportunities”.
  10. McElrath MJ, Smythe K, Randolph-Habecker J, Melton KR, Goodpaster TA, Hughes SM, Mack M, Sato A, Diaz G, Steinbach G, Novak RM, Curlin M, Lord JD, Maenza J, Duerr A, Frahm N, Hladik F. Comprehensive assessment of HIV target cells in the distal human gut suggests increasing HIV susceptibility toward the anus. Journal of AIDS 63:263-271 (2013).
  11. Ballweber L, Robinson B, Kreger A, Fialkow M, Lentz G, McElrath MJ, Hladik F. Vaginal Langerhans cells non-productively transporting HIV-1 mediate infection of T cells. Journal of Virology 85:13443-13447 (2011).
  12. McElrath MJ, Ballweber L, Terker A, Kreger A, Sakchalathorn P, Robinson B, Lentz G, Fialkow M, Hladik F. Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells. Antimicrobial Agents and Chemotherapy 54:763-772 (2010).
  13. Doehle BP, Hladik F, McNevin JP, McElrath MJ, Gale M Jr. Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. Journal of Virology 83:10395-10405, 2009.
  14. Zhu J, Hladik F, Woodward A, Klock A, Peng T, Johnston C, Remington M, Magaret A, Koelle DM, Wald A, Corey L. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nature Medicine 15:886-893 (2009).
  15.  immunity_mag_2-2007Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, Eschenbach D, McElrath MJ. Initial events in establishing vaginal HIV-1 entry and infection. Immunity 26:257-570 (2007).
  16. Zhu J, Koelle DM, Cao J, Vazquez J, Huang ML, Hladik F, Wald A, Corey L. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. Journal of Experimental Medicine 19:595-603 (2007).
  17. Hladik F, Liu H, Speelmon E, Livingston-Rosanoff D, Wilson S, Sakchalathorn P, Zhu T, McElrath MJ. Combined effect of CCR5Δ32 heterozygosity and CCR5 promoter polymorphism A -2459G on CCR5 expression and resistance to sexual HIV-1 transmission. Journal of Virology 79:11677-11684 (2005).
  18. Hladik F, Desbien A, Lang J, Wang L, Ding Y, Holte S, Wilson A, Xu J, Moerbe M, Schmechel S, McElrath MJ. Most highly exposed seronegative men lack HIV-1-specific, IFN-γ secreting T cells. Journal of Immunology 171:2671-2683 (2003).


Complete List of Published Work in MyBibliography